Endocrinology providers, Certified diabetes care and education specialists, Primary care providers, Physicians, NPs, PAs
Incretins, GLP-1 RA, shared decision-making, social determinants of health, obesity, weight management, bariatric surgery, type 2 diabetes
Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM
Director of Pharmacy Education
Department of Clinical Pharmacy and Outcomes Science
University of South Carolina School of Medicine Greenville
Greenville, South Carolina
Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM, is a Clinical Professor and the Director of Pharmacy Education at the University of South Carolina College of Pharmacy at the School of Medicine, Greenville Campus. Dr. Clements earned her PharmD from Campbell University in 2006 and completed a primary care pharmacy practice residency in 2007 at the Ralph H. Johnson VA Medical Center (VAMC) in Charleston, South Carolina.
Dr. Clements began her academic career in 2007, holding full-time faculty appointments with Shenandoah University before transitioning to the Presbyterian College School of Pharmacy, where she served as Professor and Director of Postgraduate Education. During her academic tenure, she developed pharmacy practice sites in a VAMC and rural health family medicine clinic with a focus on chronic disease state management, specifically diabetes and obesity. From 2019-2022, Dr. Clements provided medication management for people with diabetes within an interprofessional practice model, where she oversaw inpatient diabetes management at Spartanburg Regional Healthcare System, a 1000+ bed for the healthcare system, and chaired the health system’s Diabetes Advisory Council. She has authored numerous publications and presentations related to diabetes and obesity pharmacotherapy.
Dr. Clements is an active member of the American Association of Clinical Endocrinology, American Diabetes Association, Association of Diabetes Care and Education Specialists (ADCES), American Society of Health-System Pharmacists, and American College of Clinical Pharmacy (ACCP). She was honored as fellow within ADCES in 2021 and ACCP in 2017. She is a board-certified pharmacotherapy specialist, board-certified ambulatory care pharmacist, certified diabetes care and education specialist, and board certified in advanced diabetes management.
Carol Hatch Wysham, MD
Clinical Professor of Medicine
University of Washington
Rockwood Center for Diabetes and Endocrinology
Rockwood Clinic/MultiCare Health System
Carol Hatch Wysham, MD, is a Clinical Professor of Medicine at the University of Washington School of Medicine and Clinical Endocrinologist at Rockwood Clinic/MultiCare Health System in Spokane, Washington. Dr. Wysham earned her medical degree at the University of Iowa College of Medicine. She completed an internship and residency in internal medicine at Oregon Health Sciences University and a fellowship in endocrinology and metabolism at the University of Iowa Hospitals and Clinics. She is certified by the American Board of Internal Medicine with subspecialty certification in endocrinology and metabolism.
Dr. Wysham’s research interests, spanning more than 30 years, have focused on the prevention of cardiovascular disease in type 2 diabetes. Her clinical interests are in advanced technologies in type 1 and type 2 diabetes, with a focus on treatment of older adults.
Dr. Wysham is a Fellow of the American College of Physicians and a member of the American Diabetes Association and the Endocrine Society. She has served as member and Chair of the American Diabetes Association Clinical Practice Committee; has served as a member, Co-Chair, and Chair of the Annual Meeting Steering Committee of the Endocrine Society; and is the immediate Past-President of the Endocrine Society. She has written numerous articles for scientific journals including JAMA, Diabetes Care, and Lancet.
|1.||Apply the latest evidence-based guidelines and clinical practice recommendations to the management of T2D that reflect the importance of early therapy intensification to meet individualized patient needs||2.||Develop strategies that foster shared decision-making and practical approaches for weight management as part of T2D management|
|3.||Design treatment plans that address weight loss as a primary treatment target for T2D|
|1.||Apply the latest evidence-based guidelines and clinical practice recommendations to the management of T2D that reflect the importance of early therapy intensification to meet individualized patient needs|
|2.||Develop strategies that foster shared decision-making and practical approaches for weight management as part of T2D management|
|3.||Design treatment plans that address weight loss as a primary treatment target for T2D|
A “Do It Better” Challenge: Can You Improve Outcomes for Patients With Obesity and Type 2 Diabetes?
Targeting Weight Loss in T2D: Bringing Patients to the Table
Provided by Clinical Care Options, LLC , in partnership with the Association of Diabetes Care & Education Specialists.
This activity is supported by an educational grant from Lilly.
Upon completion of this activity, learners should be able to:
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity.
Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM: consultant/advisor/speaker: Novo Nordisk, Sanofi.
Carol Hatch Wysham, MD: researcher: Abbott, Corcept, Lilly, Novo Nordisk, Regeneron, Vanda.
CCO and ADCES staff and planners have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Learners have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by healthcare professionals without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This program is intended for endocrinology providers (physicians, nurse practitioners, and physician associates/physician assistants), certified diabetes care and education specialists, and primary care providers (physicians, nurse practitioners, and physician associates/physician assistants), including those who care for underserved populations.
The goal of this activity is to improve the competence of endocrinologists and certified diabetes care and education specialists and provide them with practical strategies for early intensification of T2D management that prioritizes sustained weight loss to improve long-term outcomes in patients with T2D and overweight or obesity.
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC and Association of Diabetes Care & Education Specialists. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Designation of Credit
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.
Continuing Pharmacy Education
CCO designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-218-H01-P.
Type of Activity: Knowledge
Upon successfully completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Assistant/Physician Associate Continuing Medical Education
Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until Expiration: 9/22/23. PAs should only claim commensurate with the extent of their participation.
Registered Dieticians/Dietetic Technicians, Registered
Registered Dietitians/Dietetic Technicians, Registered will receive 0.5 Continuing Professional Education units (CPEUs) for completion of this activity.
Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU. RDs and DTRs are to select activity type 102 in their Activity Log. Performance Indicator selection is at the learner’s discretion.
COURSE VIEWING REQUIREMENTS
|Supported Browsers: |
Google Chrome 60 or higher
Mozilla Firefox 60 or higher
Apple Safari 11.0 or higher
For video, install the latest version of Quicktime.
|Supported Phones & Tablets: |
iOS 9.3 and higher
Android 7.0 (Nougat or higher)
Microsoft Windows 8
|Additional Recommendations and Requirements|
|Display Resolution & Color Depth||Resolution |
- 960 X 768 minimum
- 1024 X 768 recommended min.
- 8 bits (256 colors) minimum
- 16 bits (High colors) minimum
|Audio||- Microphone |
- Speakers or headphones
- Audio recording support
|Word Processing||Software that can open, modify, and save documents in Rich Text Format (RTF). Microsoft Word and PowerPoint are recommended.|